R 7050 (C09-1025-906)

Shipped at room temperature. Store at -20°C.R-7050 is a TNF-α receptor signaling antagonist.TNF-α induces biological activity throgh stimulation of the tumor necrosis factor receptor. Although plenty of pre-clinical and clinical evidence suggests a detrimental role, small molecule TNF-αsignaling pathway inhibitors remain largely unexplored in the context of a brain hemorrhage.In vitro: R-7050 was identified as a selective inhibitot of TNF-α induced cellular signaling by using differential library screening. Unlike biologic TNF inhibitors directly binding TNF-α, R-7050 could not affect binding of TNF-α to TNFR. In contrast, R-7050 was able to selectively inhibit the association of TNF receptor with intracellular adaptor molecules In vivo:In previous animal study, R-7050 was tested to attenuate neurovascular injury after Intracerebral hemorrhage (ICH) in mice. Results showed that up to 2h post-injury administration of R-7050 was able to significantly reduce blood-brain barrier opening and attenuate edema development at 24h post-ICH. In addition, neurological outcomes were also improved over the first 3 days after injury. Whereas, R-7050 was not found to be albe to reduce hematoma volume, indicating the beneficial effects of TNFR inhibition were downstream of clot formation/resolution .Clinical trial:Up to now, R-7050 is still in the preclinical development stage. Specification: ≥99% Molecular Formula: C16H8ClF3N4S Molecular Weight: 380.77 PubChem CID: 1486608 Isomeric SMILES: C1=CC=C(C=C1)SC2=NC3=C(C=C(C=C3)Cl)N4C2=NN=C4C(F)(F)F Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/R276233-SCI_b81633ba6e42d5216ca3203d91cc99ac.pdf